Semaglutide 2.4mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

被引：0
|
作者：
Garvey, T. W. [1 ]
Holst-Hansen, T. [2 ]
Laursen, P. N. [2 ]
Rinnov, A. R. [2 ]
Wilkinson, L. [3 ]
机构：
[1] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA
[2] Novo Nordisk AS, Soborg, Denmark
[3] Novo Nordisk Inc, Plainsboro, NJ USA
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
562
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [1] Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity
    Garvey, W. Timothy
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Wilkinson, Lua J.
    DIABETES, 2022, 71
  • [2] Effect of semaglutide 2.4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity
    Wilkinson, Lua
    Holst-Hansen, Thomas
    Laursen, Peter N.
    Rinnov, Anders R.
    Batterham, Rachel L.
    Garvey, W. Timothy
    OBESITY, 2023, 31 (09) : 2249 - 2259
  • [3] Tirzepatide versus Semaglutide 2.4 mg for People with Obesity or Overweight and Type 2 Diabetes
    Hankosky, Emily
    Brumm, Julia Fraseur
    Malik, Raleigh
    Niemeyer, Anthony
    Wang, Fangyu
    Zhang, Xiaotian Michelle
    He, Xuanyao
    OBESITY, 2023, 31 : 83 - 84
  • [4] THE COST-EFFECTIVENESS OF SEMAGLUTIDE 2.4MG IN PATIENTS WITH OVERWEIGHT/OBESITY AND CARDIOVASCULAR DISEASE FROM THE SELECT TRIAL
    McEwan, P.
    Bog, M.
    Faurby, M.
    Foos, V
    Lingvay, I
    Lubker, C.
    Miller, R.
    Toliver, J.
    Yeates, F.
    Lincoff, A. M.
    VALUE IN HEALTH, 2024, 27 (06) : S148 - S148
  • [5] Influence of baseline characteristics on weight loss with semaglutide 2.4 mg in adults with overweight/obesity and type 2 diabetes (STEP 2)
    Le Roux, C. W.
    Faerch, L.
    Holst-Hansen, T.
    Koroleva, A.
    Kushner, R. F.
    Lim, S.
    Lingvay, I.
    Mosenzon, O.
    Wadden, T. A.
    Garvey, W. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 235 - 236
  • [6] Influence of Baseline Characteristics on Weight Loss with Semaglutide 2.4 mg in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2)
    Lingvay, Ildiko
    Faerch, Louise
    Koroleva, Anna
    Kushner, Robert F.
    Le Roux, Carel
    Lim, Soo
    Mosenzon, Ofri
    Wadden, Thomas A.
    Wallenstein, Signe O. R.
    Timothy Garvey, W.
    DIABETES, 2021, 70
  • [7] Semaglutide 2.4 mg Improves Health -Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial
    Rubino, Domenica
    Faerch, Louise
    Meincke, Henrik H.
    Kushner, Robert F.
    Pedersen, Sue
    Ryan, Donna H.
    Wharton, Sean
    Zeuthen, Niels
    Kolotkin, Ronette
    DIABETES, 2021, 70
  • [8] Effect of semaglutide 2.4 mg on glucose metabolism and body weight in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial
    Pedersen, S. D.
    Davies, M.
    Faerch, L.
    Jeppesen, O. K.
    Pakseresht, A.
    Perreault, L.
    Rosenstock, J.
    Shimomura, I.
    Viljoen, A.
    Wadden, T.
    Lingvay, I.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 13 - 13
  • [9] Effect of Semaglutide 2.4 mg on Glucose Metabolism and Body Weight in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial
    Perreault, Leigh
    Davies, Melanie J.
    Faerch, Louise
    Jeppesen, Ole
    Pakseresht, Arash
    Pedersen, Sue
    Rosenstock, Julio
    Shimomura, Iichiro
    Viljoen, Adie
    Wadden, Thomas A.
    Lingvay, Ildiko
    DIABETES, 2021, 70
  • [10] 10-year risk of fractures (FRAX) in people with diabetes type 2
    Mazurenko, E. S.
    Malutina, S. K.
    Shcherbakova, L., V
    Hrapova, Yu, V
    Isaeva, M. P.
    Rymar, O. D.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (10) : 76 - 81
12345